2015
DOI: 10.1038/jid.2014.372
|View full text |Cite
|
Sign up to set email alerts
|

KIT Is a Frequent Target for Epigenetic Silencing in Cutaneous Melanoma

Abstract: The receptor tyrosine kinase KIT and its ligand, stem cell factor (SCF), are essential for the proliferation and survival of normal melanocytes. In melanomas arising on mucosal, acral, and chronically sun-damaged skin, activating KIT mutations have been identified as oncogenic drivers and potent therapeutic targets. Through an initial whole-genome screen for aberrant promoter methylation in melanoma, we identified the KIT promoter as a target for hypermethylation in 43/110 melanoma cell lines, and in 3/12 prim… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

3
44
0
2

Year Published

2015
2015
2020
2020

Publication Types

Select...
7
2

Relationship

0
9

Authors

Journals

citations
Cited by 43 publications
(49 citation statements)
references
References 41 publications
3
44
0
2
Order By: Relevance
“…c-KIT mutations can activate the signal transduction cascades that regulate cell proliferation, apoptosis, chemotaxis and adhesion [25]. In GIST tumors, activating mutations of c-KIT were detected, but also the loss or down-regulation of the c-KIT can be observed linked to neoplastic transformation as for example in breast carcinoma and melanoma [11, 12]. Few and dated studies have analyzed c-KIT expression profiles in thyroid tumors [13–16], finding a correlation with differentiation and growth control of thyroid epithelium and also suggesting a c-KIT loss of function in malignant transformation.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…c-KIT mutations can activate the signal transduction cascades that regulate cell proliferation, apoptosis, chemotaxis and adhesion [25]. In GIST tumors, activating mutations of c-KIT were detected, but also the loss or down-regulation of the c-KIT can be observed linked to neoplastic transformation as for example in breast carcinoma and melanoma [11, 12]. Few and dated studies have analyzed c-KIT expression profiles in thyroid tumors [13–16], finding a correlation with differentiation and growth control of thyroid epithelium and also suggesting a c-KIT loss of function in malignant transformation.…”
Section: Discussionmentioning
confidence: 99%
“…There are papers showing that c-KIT is highly expressed or mutated in small cell lung cancer [7], leukemia cells [8], colon cancer [9] and neuroblastoma [10]. On the other hand, c-KIT expression is lost in breast cancer [11] and melanoma [12]. Some studies investigated c-KIT expression in thyroid gland and in thyroid malignancies [13–16], suggesting a role for this receptor and its ligand in differentiation and growth control of thyroid epithelium and that this function may be lost following malignant transformation.…”
Section: Introductionmentioning
confidence: 99%
“…Paradoxically, KIT expression is either low or undetectable in this latter category of melanomas, which are primarily driven by either BRAF or NRAS activating mutations (1113). The loss of KIT expression has been attributed to frequent deletion or hypermethylation of the KIT locus in melanoma (14,15). While the loss of KIT in cutaneous melanomas is well documented, it remains unclear whether this loss is a cause or consequence of tumorigenesis.…”
Section: Introductionmentioning
confidence: 99%
“…Moreover, TYR had many interactions with other DEGs and was a hub node in the PPI network, implying predominant roles in the biological processes of pigmentation. Additionally, the up-regulated KIT , which was previously identified as a oncogenic drivers in sun-impaired skin, was annotated as a potential oncogene in this study [29]. …”
Section: Discussionmentioning
confidence: 99%